GO2 for Lung Cancer Addresses Disparities and Health Inequities Head-On in Underserved Communities

Through efforts in awareness, education and readily available resources, GO2 for Lung Cancer is helping underserved communities access information and education needed to increase survival rates.

NEW YORK, Jan. 23, 2023 /PRNewswire-PRWeb/ -- GO2 for Lung Cancer (GO2), a leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer, is committing to continue their efforts to increase awareness and be a resource for those in underserved communities who are at risk or affected by lung cancer.

The organization is tackling the issue of lung health disparities in minority communities to address concerning figures that are prevalent among Black Americans, women, Latinos and Asians in the United States.

Lung cancer is the leading cause of cancer deaths among Black Americans, women, Asians and Latinos in the U.S. It is estimated that in 2022, 61,360 women and 14,160 Black Americans died from lung cancer. Additionally, Black Americans and Asian Americans are under-represented in clinical trials (3% Asian Americans, 6% Black Americans, 83% Caucasians) and it has also been found that women who never smoked are more than twice as likely to get lung cancer as their male counterparts.

Through recent efforts (listed below) and current on-going studies, GO2 is directly involved in addressing these health disparities. The organization is committed to working with health professionals and government officials to address specific concerns and needs for under-resourced communities:

• The "Alabama Lung Cancer Awareness, Screening, and Education" (ALCASE) project was a joint effort between the University of Alabama at Birmingham's O'Neal Comprehensive Cancer Center (UAB) and GO2 to increase awareness, increase access to quality screening and assist those at high risk of lung cancer in largely rural, primarily underserved and predominately Black communities in Alabama.
• The "Studying Trial Determinates of Success" (STRIDES) Study is a collaboration with GO2, Vanderbilt University, UAB, and Augusta University designed to understand and address barriers to clinical trial participation in Black communities in Alabama, Tennessee, and Georgia.
• The "Women's Health Access Matters" (WHAM) Report on Lung Cancer is a study released in partnership with GO2 showing the staggering economic benefits of investing in research focused on women and lung cancer.

GO2 offers direct one-on-one individualized professional support through their HelpLine call-center - a completely free resource for lung cancer patients who are seeking educational materials; guidance on screening, treatment clinical trial information and referrals. GO2's trained HelpLine team is readily available to take calls Monday ? Friday 9am-5pm EST.

GO2 also offers lung cancer patients the Phone Buddy Program: Peer-to-peer program connecting patients with lung cancer survivors with a similar diagnosis, the GUIDES Program: Peer-to-peer program for caregivers whose loved one is at the end of life or has died, as well as a Support Group Network, all for free.

"GO2 is committed to confronting lung cancer and reducing disparities among under-resourced communities. We are committed to achieving health equity and improving the lives of those vulnerable, at risk and diagnosed with lung cancer. We aim to make it as seamless as possible to get those at risk the most accurate and up-to-date information available to help increase their chances of survivorship," said Laurie Fenton Ambrose, co-founder, president, and CEO of GO2.

Visit GO2's website to learn more about the current undergoing studies and the life-saving information they provide to assist individuals confronting lung cancer.

About GO2 for Lung Cancer
GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day. Founded by patients and survivors, we are dedicated to increasing survival for those at risk, diagnosed and living with lung cancer. For more information, visit go2.org.

Media Contact

Julia Perry, GO2 for Lung Cancer (GO2), 916.658.0144, [email protected]

SOURCE GO2 for Lung Cancer (GO2)